# Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents

> **NCT00645411** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 3604 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Cell culture-derived influenza subunit vaccine (cTIV)
- **BIOLOGICAL:** Egg derived influenza subunit vaccine (eTIV)
- **BIOLOGICAL:** Cell culture-derived influenza subunit vaccine (cTIV)
- **BIOLOGICAL:** Egg derived influenza subunit vaccine (eTIV)

## Key facts

- **NCT ID:** NCT00645411
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-02
- **Final completion:** 2008-07
- **Target enrollment:** 3604 (ACTUAL)
- **Last updated:** 2015-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00645411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00645411, "Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00645411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*